Prolonged Neurological and Musculoskeletal Symptoms Following Shingrix Vaccination
<b>Background and Clinical Significance</b>: The recombinant zoster vaccine (Shingrix) helps prevent shingles and its complications in adults 50 and older. While minor side effects are common, severe adverse reactions are thought to be rare, and long-term side effects are not well docume...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Reports |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2571-841X/7/4/83 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850085633124466688 |
|---|---|
| author | Sabrina Hollar Amna Khalid Benjamin D. Brooks Michael Wons |
| author_facet | Sabrina Hollar Amna Khalid Benjamin D. Brooks Michael Wons |
| author_sort | Sabrina Hollar |
| collection | DOAJ |
| description | <b>Background and Clinical Significance</b>: The recombinant zoster vaccine (Shingrix) helps prevent shingles and its complications in adults 50 and older. While minor side effects are common, severe adverse reactions are thought to be rare, and long-term side effects are not well documented. <b>Case Presentation</b>: A 50-year-old woman with Crohn’s disease developed joint pain, effusion, and neurological symptoms such as numbness and tingling shortly after receiving the first dose of the recombinant zoster vaccine. Symptoms waxed and waned but persisted for over a year despite anti-inflammatories and specialist referrals. Diagnostic imaging and labs were unrevealing. <b>Conclusions</b>: This case of prolonged somatic and neurological symptoms associated temporally with Recombinant zoster vaccine administration reinforces the critical need for thorough pharmacovigilance and investigation of possible long-term adverse vaccine reactions. Provider documentation and reporting of individual experiences can help improve the detection of rare vaccine-related risks, elucidate potential risk factors, and refine safety screening. Diligent monitoring and research into longitudinal vaccine outcomes remain paramount, especially following recent emergency authorizations. |
| format | Article |
| id | doaj-art-ea711ddf977c4e4a88e8a3406572e83f |
| institution | DOAJ |
| issn | 2571-841X |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Reports |
| spelling | doaj-art-ea711ddf977c4e4a88e8a3406572e83f2025-08-20T02:43:39ZengMDPI AGReports2571-841X2024-10-01748310.3390/reports7040083Prolonged Neurological and Musculoskeletal Symptoms Following Shingrix VaccinationSabrina Hollar0Amna Khalid1Benjamin D. Brooks2Michael Wons3Department of Biomedical Sciences, Rocky Vista University, Parker, CO 80134, USADepartment of Biomedical Sciences, Rocky Vista University, Ivins, UT 84738, USADepartment of Biomedical Sciences, Rocky Vista University, Ivins, UT 84738, USADepartment of Biomedical Sciences, Rocky Vista University, Ivins, UT 84738, USA<b>Background and Clinical Significance</b>: The recombinant zoster vaccine (Shingrix) helps prevent shingles and its complications in adults 50 and older. While minor side effects are common, severe adverse reactions are thought to be rare, and long-term side effects are not well documented. <b>Case Presentation</b>: A 50-year-old woman with Crohn’s disease developed joint pain, effusion, and neurological symptoms such as numbness and tingling shortly after receiving the first dose of the recombinant zoster vaccine. Symptoms waxed and waned but persisted for over a year despite anti-inflammatories and specialist referrals. Diagnostic imaging and labs were unrevealing. <b>Conclusions</b>: This case of prolonged somatic and neurological symptoms associated temporally with Recombinant zoster vaccine administration reinforces the critical need for thorough pharmacovigilance and investigation of possible long-term adverse vaccine reactions. Provider documentation and reporting of individual experiences can help improve the detection of rare vaccine-related risks, elucidate potential risk factors, and refine safety screening. Diligent monitoring and research into longitudinal vaccine outcomes remain paramount, especially following recent emergency authorizations.https://www.mdpi.com/2571-841X/7/4/83recombinant zoster vaccineShingrixadverse reactionjoint painneurological symptomslong-term symptoms |
| spellingShingle | Sabrina Hollar Amna Khalid Benjamin D. Brooks Michael Wons Prolonged Neurological and Musculoskeletal Symptoms Following Shingrix Vaccination Reports recombinant zoster vaccine Shingrix adverse reaction joint pain neurological symptoms long-term symptoms |
| title | Prolonged Neurological and Musculoskeletal Symptoms Following Shingrix Vaccination |
| title_full | Prolonged Neurological and Musculoskeletal Symptoms Following Shingrix Vaccination |
| title_fullStr | Prolonged Neurological and Musculoskeletal Symptoms Following Shingrix Vaccination |
| title_full_unstemmed | Prolonged Neurological and Musculoskeletal Symptoms Following Shingrix Vaccination |
| title_short | Prolonged Neurological and Musculoskeletal Symptoms Following Shingrix Vaccination |
| title_sort | prolonged neurological and musculoskeletal symptoms following shingrix vaccination |
| topic | recombinant zoster vaccine Shingrix adverse reaction joint pain neurological symptoms long-term symptoms |
| url | https://www.mdpi.com/2571-841X/7/4/83 |
| work_keys_str_mv | AT sabrinahollar prolongedneurologicalandmusculoskeletalsymptomsfollowingshingrixvaccination AT amnakhalid prolongedneurologicalandmusculoskeletalsymptomsfollowingshingrixvaccination AT benjamindbrooks prolongedneurologicalandmusculoskeletalsymptomsfollowingshingrixvaccination AT michaelwons prolongedneurologicalandmusculoskeletalsymptomsfollowingshingrixvaccination |